XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Disaggregation of Revenue (Parenthetical) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation Of Revenue [Line Items]        
Total revenues $ 10,012 $ 9,059 $ 30,871 $ 25,395
YUTIQ [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenues [1] 7,273 3,928 19,305 11,124
YUTIQ [Member] | Ocumension Therapeutics [Member] | Supply Agreement [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenues 4 0 71 19
DEXYCU [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenues [2] 2,447 4,659 10,743 13,003
DEXYCU [Member] | Ocumension Therapeutics [Member] | Supply Agreement [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenues $ 16 $ 32 $ 16 $ 32
[1] Included approximately $4 and $71 of revenue from YUTIQ product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2022, respectively, and approximately $0 and $19 of revenue from YUTIQ product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2021, respectively.
[2] Included approximately $16 of revenue from DEXYCU product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2022, respectively, and approximately $32 of revenue from DEXYCU product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2021, respectively.